Therapeutic arteriogenesis by ultrasound-mediated VEGF165 plasmid gene delivery to chronically ischemic skeletal muscle

Howard Leong-Poi, Michael A. Kuliszewski, Michael Lekas, Matthew Sibbald, Krystyna Teichert-Kuliszewska, Alexander L. Klibanov, Duncan J. Stewart, Jonathan Lindner

    Research output: Contribution to journalArticle

    140 Citations (Scopus)

    Abstract

    Current methods of gene delivery for therapeutic angiogenesis are invasive, requiring either intraarterial or intramuscular administration. A noninvasive method of gene delivery has been developed using ultrasound-mediated destruction of intravenously administered DNA-bearing carrier microbubbles during their microcirculatory transit. Here we show that chronic ischemia could be markedly improved by ultrasound-mediated destruction of microbubbles bearing vascular endothelial growth factor-165 (VEGF165) plasmid DNA. Using a model of severe chronic hindlimb ischemia in rats, we demonstrated that ultrasound mediated VEGF165/green fluorescent protein (GFP) plasmid delivery resulted in a significant improvement in microvascular blood flow by contrast-enhanced ultrasound, and an increased vessel density by fluorescent microangiography, with minimal changes in control groups. The improvement in tissue perfusion was attributed predominantly to increases in noncapillary blood volume or arteriogenesis, with perfusion peaking at 14 days after delivery, followed by a partial regression of neovascularization at 6 weeks. Transfection was localized predominantly to the vascular endothelium of arterioles in treated ischemic muscle. RT-PCR confirmed the presence of VEGF165/GFP mRNA within treated ischemic muscle, being highest at day 3 postdelivery, and subsequently decreasing, becoming almost undetectable by 6 weeks. We found a modulation of endogenous growth factor expression in VEGF-treated ischemic muscle, consistent with a biologic effect of ultrasound mediated gene delivery. The results of our study demonstrate the utility of ultrasonic destruction of plasmid-bearing microbubbles to induce therapeutic arteriogenesis in the setting of severe chronic ischemia.

    Original languageEnglish (US)
    Pages (from-to)295-303
    Number of pages9
    JournalCirculation Research
    Volume101
    Issue number3
    DOIs
    StatePublished - Aug 2007

    Fingerprint

    Microbubbles
    Skeletal Muscle
    Plasmids
    Ischemia
    Green Fluorescent Proteins
    Muscles
    Perfusion
    Genes
    DNA
    Vascular Endothelium
    Arterioles
    Hindlimb
    Blood Volume
    Ultrasonics
    Vascular Endothelial Growth Factor A
    Transfection
    Intercellular Signaling Peptides and Proteins
    Therapeutics
    Polymerase Chain Reaction
    Control Groups

    Keywords

    • Angiogenesis
    • Chronic ischemia
    • Contrast ultrasound
    • Gene therapy
    • Peripheral vascular disease

    ASJC Scopus subject areas

    • Physiology
    • Cardiology and Cardiovascular Medicine

    Cite this

    Therapeutic arteriogenesis by ultrasound-mediated VEGF165 plasmid gene delivery to chronically ischemic skeletal muscle. / Leong-Poi, Howard; Kuliszewski, Michael A.; Lekas, Michael; Sibbald, Matthew; Teichert-Kuliszewska, Krystyna; Klibanov, Alexander L.; Stewart, Duncan J.; Lindner, Jonathan.

    In: Circulation Research, Vol. 101, No. 3, 08.2007, p. 295-303.

    Research output: Contribution to journalArticle

    Leong-Poi, H, Kuliszewski, MA, Lekas, M, Sibbald, M, Teichert-Kuliszewska, K, Klibanov, AL, Stewart, DJ & Lindner, J 2007, 'Therapeutic arteriogenesis by ultrasound-mediated VEGF165 plasmid gene delivery to chronically ischemic skeletal muscle', Circulation Research, vol. 101, no. 3, pp. 295-303. https://doi.org/10.1161/CIRCRESAHA.107.148676
    Leong-Poi, Howard ; Kuliszewski, Michael A. ; Lekas, Michael ; Sibbald, Matthew ; Teichert-Kuliszewska, Krystyna ; Klibanov, Alexander L. ; Stewart, Duncan J. ; Lindner, Jonathan. / Therapeutic arteriogenesis by ultrasound-mediated VEGF165 plasmid gene delivery to chronically ischemic skeletal muscle. In: Circulation Research. 2007 ; Vol. 101, No. 3. pp. 295-303.
    @article{d7f8bc80e44f4b3b93a8177099f4cb2a,
    title = "Therapeutic arteriogenesis by ultrasound-mediated VEGF165 plasmid gene delivery to chronically ischemic skeletal muscle",
    abstract = "Current methods of gene delivery for therapeutic angiogenesis are invasive, requiring either intraarterial or intramuscular administration. A noninvasive method of gene delivery has been developed using ultrasound-mediated destruction of intravenously administered DNA-bearing carrier microbubbles during their microcirculatory transit. Here we show that chronic ischemia could be markedly improved by ultrasound-mediated destruction of microbubbles bearing vascular endothelial growth factor-165 (VEGF165) plasmid DNA. Using a model of severe chronic hindlimb ischemia in rats, we demonstrated that ultrasound mediated VEGF165/green fluorescent protein (GFP) plasmid delivery resulted in a significant improvement in microvascular blood flow by contrast-enhanced ultrasound, and an increased vessel density by fluorescent microangiography, with minimal changes in control groups. The improvement in tissue perfusion was attributed predominantly to increases in noncapillary blood volume or arteriogenesis, with perfusion peaking at 14 days after delivery, followed by a partial regression of neovascularization at 6 weeks. Transfection was localized predominantly to the vascular endothelium of arterioles in treated ischemic muscle. RT-PCR confirmed the presence of VEGF165/GFP mRNA within treated ischemic muscle, being highest at day 3 postdelivery, and subsequently decreasing, becoming almost undetectable by 6 weeks. We found a modulation of endogenous growth factor expression in VEGF-treated ischemic muscle, consistent with a biologic effect of ultrasound mediated gene delivery. The results of our study demonstrate the utility of ultrasonic destruction of plasmid-bearing microbubbles to induce therapeutic arteriogenesis in the setting of severe chronic ischemia.",
    keywords = "Angiogenesis, Chronic ischemia, Contrast ultrasound, Gene therapy, Peripheral vascular disease",
    author = "Howard Leong-Poi and Kuliszewski, {Michael A.} and Michael Lekas and Matthew Sibbald and Krystyna Teichert-Kuliszewska and Klibanov, {Alexander L.} and Stewart, {Duncan J.} and Jonathan Lindner",
    year = "2007",
    month = "8",
    doi = "10.1161/CIRCRESAHA.107.148676",
    language = "English (US)",
    volume = "101",
    pages = "295--303",
    journal = "Circulation Research",
    issn = "0009-7330",
    publisher = "Lippincott Williams and Wilkins",
    number = "3",

    }

    TY - JOUR

    T1 - Therapeutic arteriogenesis by ultrasound-mediated VEGF165 plasmid gene delivery to chronically ischemic skeletal muscle

    AU - Leong-Poi, Howard

    AU - Kuliszewski, Michael A.

    AU - Lekas, Michael

    AU - Sibbald, Matthew

    AU - Teichert-Kuliszewska, Krystyna

    AU - Klibanov, Alexander L.

    AU - Stewart, Duncan J.

    AU - Lindner, Jonathan

    PY - 2007/8

    Y1 - 2007/8

    N2 - Current methods of gene delivery for therapeutic angiogenesis are invasive, requiring either intraarterial or intramuscular administration. A noninvasive method of gene delivery has been developed using ultrasound-mediated destruction of intravenously administered DNA-bearing carrier microbubbles during their microcirculatory transit. Here we show that chronic ischemia could be markedly improved by ultrasound-mediated destruction of microbubbles bearing vascular endothelial growth factor-165 (VEGF165) plasmid DNA. Using a model of severe chronic hindlimb ischemia in rats, we demonstrated that ultrasound mediated VEGF165/green fluorescent protein (GFP) plasmid delivery resulted in a significant improvement in microvascular blood flow by contrast-enhanced ultrasound, and an increased vessel density by fluorescent microangiography, with minimal changes in control groups. The improvement in tissue perfusion was attributed predominantly to increases in noncapillary blood volume or arteriogenesis, with perfusion peaking at 14 days after delivery, followed by a partial regression of neovascularization at 6 weeks. Transfection was localized predominantly to the vascular endothelium of arterioles in treated ischemic muscle. RT-PCR confirmed the presence of VEGF165/GFP mRNA within treated ischemic muscle, being highest at day 3 postdelivery, and subsequently decreasing, becoming almost undetectable by 6 weeks. We found a modulation of endogenous growth factor expression in VEGF-treated ischemic muscle, consistent with a biologic effect of ultrasound mediated gene delivery. The results of our study demonstrate the utility of ultrasonic destruction of plasmid-bearing microbubbles to induce therapeutic arteriogenesis in the setting of severe chronic ischemia.

    AB - Current methods of gene delivery for therapeutic angiogenesis are invasive, requiring either intraarterial or intramuscular administration. A noninvasive method of gene delivery has been developed using ultrasound-mediated destruction of intravenously administered DNA-bearing carrier microbubbles during their microcirculatory transit. Here we show that chronic ischemia could be markedly improved by ultrasound-mediated destruction of microbubbles bearing vascular endothelial growth factor-165 (VEGF165) plasmid DNA. Using a model of severe chronic hindlimb ischemia in rats, we demonstrated that ultrasound mediated VEGF165/green fluorescent protein (GFP) plasmid delivery resulted in a significant improvement in microvascular blood flow by contrast-enhanced ultrasound, and an increased vessel density by fluorescent microangiography, with minimal changes in control groups. The improvement in tissue perfusion was attributed predominantly to increases in noncapillary blood volume or arteriogenesis, with perfusion peaking at 14 days after delivery, followed by a partial regression of neovascularization at 6 weeks. Transfection was localized predominantly to the vascular endothelium of arterioles in treated ischemic muscle. RT-PCR confirmed the presence of VEGF165/GFP mRNA within treated ischemic muscle, being highest at day 3 postdelivery, and subsequently decreasing, becoming almost undetectable by 6 weeks. We found a modulation of endogenous growth factor expression in VEGF-treated ischemic muscle, consistent with a biologic effect of ultrasound mediated gene delivery. The results of our study demonstrate the utility of ultrasonic destruction of plasmid-bearing microbubbles to induce therapeutic arteriogenesis in the setting of severe chronic ischemia.

    KW - Angiogenesis

    KW - Chronic ischemia

    KW - Contrast ultrasound

    KW - Gene therapy

    KW - Peripheral vascular disease

    UR - http://www.scopus.com/inward/record.url?scp=34548314613&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=34548314613&partnerID=8YFLogxK

    U2 - 10.1161/CIRCRESAHA.107.148676

    DO - 10.1161/CIRCRESAHA.107.148676

    M3 - Article

    C2 - 17585071

    AN - SCOPUS:34548314613

    VL - 101

    SP - 295

    EP - 303

    JO - Circulation Research

    JF - Circulation Research

    SN - 0009-7330

    IS - 3

    ER -